Last reviewed · How we verify
CT011 CAR-GPC3 T Cells Injection — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
CT011 CAR-GPC3 T Cells Injection (CT011 CAR-GPC3 T Cells Injection) — CARsgen Therapeutics Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CT011 CAR-GPC3 T Cells Injection TARGET | CT011 CAR-GPC3 T Cells Injection | CARsgen Therapeutics Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CT011 CAR-GPC3 T Cells Injection CI watch — RSS
- CT011 CAR-GPC3 T Cells Injection CI watch — Atom
- CT011 CAR-GPC3 T Cells Injection CI watch — JSON
- CT011 CAR-GPC3 T Cells Injection alone — RSS
Cite this brief
Drug Landscape (2026). CT011 CAR-GPC3 T Cells Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/ct011-car-gpc3-t-cells-injection. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab